Abstract
Purpose/Objective(s)
To evaluate the risk of second malignancies after seed migration in prostate cancer patients treated with I-125 free seeds brachytherapy.
Materials/Methods
Data from 2067 prostate cancer patients treated with I-125 free seeds brachytherapy in three Canadian centers were analyzed. Kaplan-Meier method was used to estimate the 5-and 7-year biochemical relapse-free and overall survival between patients who experienced or not seed migration.
Results
Mean age and Median follow-up was 64 years and 44 (range 1-147) months, respectively. Seed migration occurred in 365 of 2067 patients (17.7%). The 5-, 7-year biochemical relapse-free and overall survival for the entire cohort was 96%, 91.7% and 95.9%, 93.7%, respectively. Second malignancies occurred in 4 of 365 patients (1.1%) and 21 of 1702 patients (1.2%) in patients with or without seed migration, respectively (p=0.827). Lung cancer represented the most frequent second malignancy observed and occurred in 6 patients, all in the no seed migration group. The other second malignancies observed in the no seed migration group included: larynx (3 patients), colon (2 patients), esophagus (2), pancreatic (2), renal, myeloma, glioblastoma, non-Hodgkin's lymphoma (1) and 2 unknown. In the seed migration group, the Open Access Poster second malignancies observed were chronic myeloid leukemia (1), colo-rectal cancer (2) and nasopharynx (1) .
Conclusion
These results do not support an increased risk of second malignancies, particularly lung cancer with seed migration after I-125 free seeds brachytherapy for prostate cancer patients. Due to the low rate of second malignancies observed in this cohort, further studies with longer followup are required to better correlate seed migration and second malignancies.
